

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 10 returned.**☐ 1. Document ID: US 6511676 B1

L2: Entry 1 of 10

File: USPT

Jan 28, 2003

US-PAT-NO: 6511676

DOCUMENT-IDENTIFIER: US 6511676 B1

TITLE: Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

DATE-ISSUED: January 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Boulikas; Teni	Palo Alto	CA	94306	

US-CL-CURRENT: [424/450](#); [264/4.1](#), [264/4.3](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: US 6322810 B1

L2: Entry 2 of 10

File: USPT

Nov 27, 2001

US-PAT-NO: 6322810

DOCUMENT-IDENTIFIER: US 6322810 B1

TITLE: Materials and methods for making improved micelle compositions

DATE-ISSUED: November 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alkan-Onyuksel; Hayat	Western Springs	IL	60558	
Rubinstein; Israel	Highland Park	IL	60035	

US-CL-CURRENT: [424/450](#); [424/1.21](#), [424/812](#), [424/9.321](#), [424/9.51](#), [424/94.3](#), [428/402.2](#), [436/829](#), [514/21](#), [514/937](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 6217886 B1

L2: Entry 3 of 10

File: USPT

Apr 17, 2001

US-PAT-NO: 6217886

DOCUMENT-IDENTIFIER: US 6217886 B1

TITLE: Materials and methods for making improved micelle compositions

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Onyuksel; Hayat	Western Springs	IL		
Rubinstein; Israel	Highland Park	IL		

US-CL-CURRENT: 424/401; 264/4.1, 264/4.3, 264/4.6, 424/1.21, 424/450, 424/9.321,
424/9.51, 514/2, 514/21, 514/937

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 6177079 B1

L2: Entry 4 of 10

File: USPT

Jan 23, 2001

US-PAT-NO: 6177079

DOCUMENT-IDENTIFIER: US 6177079 B1

TITLE: Antagonists of interleukin-15

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 424/152.1; 424/130.1, 424/133.1, 424/141.1, 424/145.1, 530/388.1,
530/388.23, 530/389.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 5. Document ID: US 6168783 B1

L2: Entry 5 of 10

File: USPT

Jan 2, 2001

US-PAT-NO: 6168783

DOCUMENT-IDENTIFIER: US 6168783 B1

TITLE: Antagonists of interleukin-15

DATE-ISSUED: January 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 424/85.1; 424/85.2, 530/300, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 6. Document ID: US 6165466 A

L2: Entry 6 of 10

File: USPT

Dec 26, 2000

US-PAT-NO: 6165466

DOCUMENT-IDENTIFIER: US 6165466 A

TITLE: Antagonists of interleukin-15

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 424/145.1; 424/158.1, 424/172.1, 424/173.1, 530/388.23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 7. Document ID: US 6013480 A

L2: Entry 7 of 10

File: USPT

Jan 11, 2000

US-PAT-NO: 6013480

DOCUMENT-IDENTIFIER: US 6013480 A

TITLE: Antagonists of interleukin-15

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KUMC

☐ 8. Document ID: US 5795966 A

L2: Entry 8 of 10

File: USPT

Aug 18, 1998

US-PAT-NO: 5795966

DOCUMENT-IDENTIFIER: US 5795966 A

TITLE: Antagonists of interleukin-15

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA	98040	
Pettit; Dean K.	Seattle	WA	98112	
Paxton; Raymond J.	Bellevue	WA	98006	

US-CL-CURRENT: 530/388.23; 424/158.1, 435/326, 435/328, 435/335, 435/346, 435/352

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KUMC

☐ 9. Document ID: US 5660824 A

L2: Entry 9 of 10

File: USPT

Aug 26, 1997

US-PAT-NO: 5660824

DOCUMENT-IDENTIFIER: US 5660824 A

TITLE: Muscle trophic factor

DATE-ISSUED: August 26, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA	98040	
Quinn; LeBris S.	Seattle	WA	98136	
Troutt; Anthony B.	Brier	WA	98036	

US-CL-CURRENT: 424/85.2; 530/351

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KUMC

☐ 10. Document ID: WO 9832466 A1 JP 2001508783 W AU 9857737 A EP 921817 A1 EP 921817 B1 DE 69800640 E

L2: Entry 10 of 10

File: DWPI

Jul 30, 1998

DERWENT-ACC-NO: 1998-427686

DERWENT-WEEK: 200142

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Process for attachment of poly:ethylene glycol to target substrates - by reacting halogenated PEG with substrate e.g. peptide, nucleic acid, non-steroidal hormone, antibiotic or liposome

INVENTOR: FISHER, D; FRANCIS, G E ; MALIK, F

PRIORITY-DATA: 1997GB-0008055 (April 22, 1997), 1997GB-0001800 (January 29, 1997), 1997GB-0001804 (January 29, 1997), 1997GB-0004653 (March 6, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9832466 A1	July 30, 1998	E	064	A61K047/48
JP 2001508783 W	July 3, 2001		055	A61K047/48
AU 9857737 A	August 18, 1998		000	A61K047/48
EP 921817 A1	June 16, 1999	E	000	A61K047/48
EP 921817 B1	March 28, 2001	E	000	A61K047/48
DE 69800640 E	May 3, 2001		000	A61K047/48

INT-CL (IPC): A61 K 38/00; A61 K 38/22; A61 K 38/46; A61 K 47/48

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KIMC
Draw Desc	Image									

[Generate Collection](#)[Print](#)

Terms	Documents
L1 and peg	10

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST**End of Result Set**

Generate Collection

Print

L5: Entry 2 of 2

File: USPT

Dec 10, 1991

DOCUMENT-IDENTIFIER: US 5071964 A

TITLE: Protein micelles

Brief Summary Text (7):

The adhesion protein micelles of the invention can further be used for the treatment of medical conditions characterized by the presence of an excess of activated T-cells by administering LFA-3 micelles in a physiologically compatible buffer to a patient to achieve a bloodstream concentration of LFA-3 effective to inhibit the binding of the activated T-cells to other cells in the patient; the resultant bloodstream concentration of LFA-3 is preferably 0.4 to 40 nM of LFA-3. Disease states characterized by the presence of an excess of activated T-cells include multiple sclerosis, sarcoidosis, juvenile type diabetes mellitus, systemic lupus erythematosis, thyroiditis, rheumatoid arthritis, ankyloses spondylitis, primary biliary cirrhosis, autoimmune hemolytic anemia, immune thrombocytopenia purpura, myesthenia gravis, allograft rejection and graft versus host disease.

Detailed Description Text (31):

mLFA-3 micelles alone have no effect on PBL-T proliferation, but they can induce proliferation of PBL-T in the presence of submitogenic concentrations of anti-CD2 MAb's. The combination of mLFA-3 micelles (40 nM) with CD2 MAb was found to be strongly mitogenic for peripheral blood mononuclear cells (PBMC) from all donors tested (Table 7). This response was usually (9 of 10 donors) seen in the absence of exogenous IL-2, although phorbol myristate acetate (PMA) was still required for a maximal response. Proliferation induced by the combination of mLFA-3 micelles and CD2.1 MAb was generally lower than that obtained with phytohemagglutinin (PHA), while the combination of mLFA-3, CD2.1 and PMA resulted in greater thymidine incorporation than PHA alone by up to two fold in some donors. The combination of mLFA-3 and CD2.1 MAb was also mitogenic for nylon wool enriched T-cells (Table 8).

Detailed Description Text (37):

The proliferative response to mLFA-3 with CD2.1 MAb was completely blocked by both anti-LFA-3 MAb's and the 9.6 MAb. The 9.6 MAb blocks mLFA-3 binding to CD2 but is usually not comitogenic with CD2.1 MAb (Table 9). The response to mLFA-3 with CD2.1 MAb was also blocked by CD25 (anti-IL 2 receptor p55 chain) MAb suggesting that it is IL 2 dependent. The mitogenic response of PBMC or PBL-T to mLFA-3 with CD2.1 MAb was accompanied by aggregation of cells within 16 hours. These clusters could not have been the result of passive agglutination of cells by mLFA-3 micelles, because clusters were not seen with mLFA-3 in the absence of CD2.1 MAb.

WEST

Generate Collection

Print

L1: Entry 35 of 47

File: USPT

Jun 23, 1998

DOCUMENT-IDENTIFIER: US 5770570 A

TITLE: Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide

Detailed Description Text (90):

Treatment of (Tyr.sup.10 -.sup.125 I)VIP-liposome complexes with 25 mM EDTA, 1 mM HCl, or 1M NaCl caused little or no release of the bound peptide, as shown in Table 2. At alkaline pH (1mM NaOH), a small but significant proportion (16) of the bound radioactivity was reproducibly released. Dissolution of the liposomes with SDS produced near-complete peptide release into the supernatant, reflecting, presumably, uptake of the peptide into mixed detergent-lipid micelles.

WEST

Generate Collection

Print

L1: Entry 41 of 47

File: USPT

Dec 10, 1991

DOCUMENT-IDENTIFIER: US 5071964 A
TITLE: Protein micelles

Detailed Description Text (31):

mLFA-3 micelles alone have no effect on PBL-T proliferation, but they can induce proliferation of PBL-T in the presence of submitogenic concentrations of anti-CD2 MAb's. The combination of mLFA-3 micelles (40 nM) with CD2 MAb was found to be strongly mitogenic for peripheral blood mononuclear cells (PBMC) from all donors tested (Table 7). This response was usually (9 of 10 donors) seen in the absence of exogenous IL-2, although phorbol myristate acetate (PMA) was still required for a maximal response. Proliferation induced by the combination of mLFA-3 micelles and CD2.1 MAb was generally lower than that obtained with phytohemagglutinin (PHA), while the combination of mLFA-3, CD2.1 and PMA resulted in greater thymidine incorporation than PHA alone by up to two fold in some donors. The combination of mLFA-3 and CD2.1 MAb was also mitogenic for nylon wool enriched T-cells (Table 8).

Detailed Description Text (37):

The proliferative response to mLFA-3 with CD2.1 MAb was completely blocked by both anti-LFA-3 MAb's and the 9.6 MAb. The 9.6 MAb blocks mLFA-3 binding to CD2 but is usually not comitogenic with CD2.1 MAb (Table 9). The response to mLFA-3 with CD2.1 MAb was also blocked by CD25 (anti-IL 2 receptor p55 chain) MAb suggesting that it is IL 2 dependent. The mitogenic response of PBMC or PBL-T to mLFA-3 with CD2.1 MAb was accompanied by aggregation of cells within 16 hours. These clusters could not have been the result of passive agglutination of cells by mLFA-3 micelles, because clusters were not seen with mLFA-3 in the absence of CD2.1 MAb.

WEST Search History

DATE: Thursday, March 06, 2003

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

L6	L1 and (ischemia)	2	L6
L5	L1 and (multiple adj1 sclerosis)	2	L5
L4	L1 and stroke	1	L4
L3	L1 and parkinson\$	1	L3
L2	L1 and peg	10	L2
L1	micelle\$ same (vip or glucagon or secretin or IL\$)	47	L1

END OF SEARCH HISTORY